TP53 and hepatocellular carcinoma: In a recent multicenter blinded cohort study (n = 609)20, a panel of urine circulating tumor DNA (ctDNA) markers was selected and developed using HCC-associated DNA modifications, mutated TP53 gene and two methylated DNA markers GSTP1 (mGSTP1) and RASSF1A (mRASSF1a) for HCC screening.